Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Odefsey

- PMLiVE

ViiV agrees $1.5bn deal to acquire BMS’ HIV assets

Includes its entire development pipeline - from discovery to preclinical projects

- PMLiVE

GSK earns expanded approval for Volibris in Europe

Additional indication given to pulmonary arterial hypertension drug

Roche Basel Switzerland

Roche gets EU green light for Cotellic

Approved in combination with Zelboraf for melanoma

Gilead Sciences

Gilead’s HIV drug Genvoya cleared in EU

First TAF-based regimen to be approved in the US and EU

Biogen Idec building

Biogen and Sobi’s Elocta wins EU approval

First haemophilia A treatment to offer prolonged protection against bleeding

- PMLiVE

Amgen’s Kyprolis approved in Europe

Multiple myeloma drugwins licence three years after gaining US approval

EU flag

Celgene’s Vidaza wins wider approval for acute myeloid leukaemia

Elderly patients to gain access to cancer drug

Bristol-Myers Squibb (BMS) building

First data backs efficacy of BMS’ novel HIV drug

Could provide new treatment for those resistant to antiretroviral therapy

- PMLiVE

Europe’s health information systems to be modernised

Joint EC-WHO work will form a major strand of their renewedcollaboration

- PMLiVE

Novartis to make 15 drugs available at $1 a month

Comes after concerns surrounding hiked drug prices and effects on public health

- PMLiVE

ViiV boosted by positive phase III results for HIV drug Triumeq

Data reaffirms benefitsof drug in comparison to current antiretroviral medications 

- PMLiVE

New EC health director general takes office

XavierPrats Monné will report to health commissioner Dr Vytenis Andriukaitis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links